Novavax, Inc. (NVAX) Financial Analysis & Valuation | Quarter Chart

Novavax, Inc. (NVAX)

NVAX
Price: $8.67
Fair Value: 🔒
🔒score
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials... more
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization... more
Description Shares
Market Cap$1.41BExchangeNASDAQ
SectorHealthcareIndustryBiotechnology
CountryUSCEOJohn Charles Jacobs
IPO Date1995-12-05CAGR0.38%
Employees952Websitewww.novavax.com
Div. YieldPayout Ratio
Buy Back Yield-0.41%Total Yield-0.41%
NVAX chart loading...
Fundamentals Technicals
Enterprise Value$873.86MP/E Ratio3.36
Forward P/E-7.93PEG Ratio
P/S Ratio0.04P/B Ratio-0.35
P/CF Ratio-0.18P/FCF Ratio-0.18
EPS$2.58EPS Growth 1Y-293.98%
EPS Growth 3Y-130.57%EPS Growth 5Y-138%
Revenue Growth 1Y64.69%Gross Margin0.93%
Operating Margin0.4%Profit Margin0.39%
ROE-5.46%ROA0.37%
ROCE0.63%Current Ratio2.13
Quick Ratio2.1Cash Ratio0.52
Debt/Equity-1.95Interest Coverage-20.08
Altman Z Score-1.95Piotroski Score5